Bank of America Merrill Lynch ups Dr Martens to ‘buy’

by | Jul 14, 2023

(Sharecast News) – Dr Martens surged on Friday after Bank of America Merrill Lynch lifted the stock to ‘buy’, arguing that the iconic bootmaker has an “attractive value proposition”.
The bank noted that Dr Martens shares have de-rated by 25% since the IPO.

“We see opportunity to consider the stock given its more robust earnings expectations and signs of a cleaner equity story to come,” it said.

BofA ML said the shares are “simply too cheap” and that four profit warnings in the last 12 months and a recent downgrade to medium-term guidance suggest expectations have reset.

The bank also pointed out that changes are on their way. “The group is reinvesting in the business, which should help limit operational surprises, while senior personnel changes are also taking place,” it said.

BofA noted that the brand isn’t broken and that its popularity has actually improved. In addition, it forecast return on capital employed above peers.

BofA cut its price target on the stock to 165p from 210p.

At 1515 BST, the shares were up 6.4% at 134.10p.

Related articles

RBC Capital cuts Rentokil price target

RBC Capital cuts Rentokil price target

(Sharecast News) - RBC Capital Markets cut its price target on Rentokil Initial on Wednesday to 575p from 610p as it downgraded forecasts for forex and a greater back-end loading of TMX synergies, but said it believes the long-term story remains intact. The bank said...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x